SCHEMBL31069834

SCHEMBL31069834

CCNC(=O)[C@H](CC(C)C)NC(=O)[C@H](Cc1c[nH]cn1)NC(=O)CNC(=O)[C@@H](NC(=O)[C@H](C)NC(=O)[C@H](Cc1c[nH]c2ccccc12)NC(=O)[C@H](CCC(N)=O)NC(=O)[C@H](N)Cc1ccccc1)C(C)C

nearest known ligand 0.66

Predicted protein targets (top 3)

geneUniProtsupporting neighboursconfidence
▸ GRPR P30550 12/20 0.66
▸ GLP1R P43220 4/20 0.57
▸ NMBR P28336 1/20 0.56

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL29663974 0.96 GRPR (0.68) GRPRGLP1R
SCHEMBL6510905 0.95 GRPR (0.68) GRPRGLP1R
SCHEMBL2193571 0.94 GRPR (0.67) GRPRGLP1RNMBR
SCHEMBL30118089 0.94 GRPR (0.65) GRPRGLP1R
SCHEMBL38661265 0.93 GRPR (0.65) GRPRGLP1RNMBR
SCHEMBL30816315 0.91 GRPR (0.63) GRPRGLP1RNMBR
SCHEMBL31223150 0.91 GRPR (0.61) GRPRGLP1R
SCHEMBL30628977 0.91 GRPR (0.64) GRPRGLP1R
SCHEMBL30118082 0.91 GRPR (0.65) GRPRGLP1R
SCHEMBL30628996 0.91 GRPR (0.62) GRPRGLP1R

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240366812-A1 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) 2024-11-07 — — US disclosed
US-12064489-B2 Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) 2024-08-20 — — US disclosed
US-12064491-B2 Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) 2024-08-20 — — US disclosed
US-12064490-B2 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer ADVANCED ACCELERATOR APPLICATIONS INTERNATIONAL SA (CH) 2024-08-20 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20240366812-A1 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer GRPR, GIPR, CCKBR GRPR 1/4885GLP1R 7/4885NMBR 77/4885
US-12064490-B2 Radiolabeled GRPR-Antagonists for Diagnostic Imaging and Treatment of GRPR-Positive Cancer GRPR, GIPR, CCKBR GRPR 1/4885GLP1R 7/4885NMBR 77/4885
US-12064491-B2 Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer GRPR, GIPR, CCKBR GRPR 1/4885GLP1R 7/4885NMBR 77/4885
US-12064489-B2 Radiolabeled GRPR-antagonists for diagnostic imaging and treatment of GRPR-positive cancer GRPR, GIPR, CCKBR GRPR 1/4885GLP1R 7/4885NMBR 77/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback